electroCore, Inc. (ECOR) Bundle
A Brief History of electroCore, Inc. (ECOR)
Formation and Early Years
Formation and Early Years
electroCore, Inc. was founded in 2014, emerging from a vision to create non-invasive therapies for neurological conditions. The company's primary focus has been on developing a device known as gammaCore, aimed at treating cluster headaches and migraine pain.
Initial Public Offering (IPO)
In June 2018, electroCore completed its initial public offering (IPO), raising approximately $75 million at a price of $16 per share. The company was listed on the NASDAQ under the ticker symbol ECOR.
Product Development and FDA Approvals
In 2018, the U.S. Food and Drug Administration (FDA) granted de novo clearance for the gammaCore device for the acute treatment of pain associated with episodic cluster headache. In 2019, the FDA also approved the device for the treatment of migraine.
Financial Performance and Stock Price Trends
As of the close of trading on October 20, 2023, the stock price of electroCore, Inc. stood at $1.25 per share. The company's market capitalization was approximately $63 million.
Revenue Generation
In the fiscal year 2022, electroCore reported total revenue of $15.7 million, showcasing a growth compared to $9.6 million in 2021. The revenue growth was attributed to increased sales of gammaCore devices and the expansion of the product line.
Key Financial Metrics
| Year | Revenue (Million USD) | Net Loss (Million USD) | Cash and Cash Equivalents (Million USD) |
|---|---|---|---|
| 2020 | 5.2 | 24.9 | 8.3 |
| 2021 | 9.6 | 19.4 | 10.2 |
| 2022 | 15.7 | 13.5 | 15.1 |
| 2023 (Q2) | 8.1 | 6.2 | 12.5 |
Recent Developments and Product Pipeline
In 2023, electroCore announced plans to expand its clinical trials for gammaCore to include new indications, aiming at treating additional conditions such as anxiety and depression.
Market Position and Competition
As of 2023, electroCore holds a competitive edge in the non-invasive neurostimulation market, with its primary competitor being Cerbomed, which offers similar neurostimulation devices. The global market for non-invasive neuromodulation technologies was projected to be valued at around $5.9 billion by 2025.
Clinical Evidence and Partnerships
electroCore has established partnerships with various medical institutions and universities to further validate the clinical efficacy of gammaCore. Clinical trials have shown that gammaCore can significantly reduce the frequency and severity of headaches in patients suffering from chronic conditions.
A Who Owns electroCore, Inc. (ECOR)
Current Shareholders
Current Shareholders
As of the latest available data from 2023, the ownership structure of electroCore, Inc. (ECOR) reflects a mix of institutional and retail investors. The following table provides a detailed breakdown of significant shareholders:
| Shareholder Type | Number of Shares Owned | Ownership Percentage | Percentage Change (Last Year) |
|---|---|---|---|
| Institutional Investors | 4,500,000 | 40% | -5% |
| Retail Investors | 3,000,000 | 27% | +10% |
| Insiders | 1,500,000 | 13.5% | 0% |
| Mutual Funds | 2,000,000 | 18% | -3% |
Major Institutional Holders
The following table lists the major institutional holders of electroCore, Inc. as of 2023:
| Institution Name | Shares Owned | Ownership Percentage | Market Value (in USD) |
|---|---|---|---|
| The Vanguard Group, Inc. | 1,200,000 | 10.67% | 6,600,000 |
| BlackRock, Inc. | 1,000,000 | 8.89% | 5,500,000 |
| State Street Corporation | 600,000 | 5.33% | 3,300,000 |
| Wellington Management Company LLP | 800,000 | 7.11% | 4,400,000 |
Executive Ownership
The executive team at electroCore, Inc. also holds a notable percentage of the company. The following table illustrates the ownership by key executives:
| Executive Name | Title | Shares Owned | Ownership Percentage |
|---|---|---|---|
| Dan Goldberger | CEO | 500,000 | 4.45% |
| Dr. John D. McGhee | Chief Medical Officer | 200,000 | 1.78% |
| Mark J. S. Kauffman | CFO | 150,000 | 1.33% |
Recent Financial Performance
According to the most recent quarterly report, the financial performance of electroCore, Inc. is as follows:
| Fiscal Quarter | Total Revenue (in USD) | Net Loss (in USD) | Cash Reserves (in USD) |
|---|---|---|---|
| Q1 2023 | 1,200,000 | -2,000,000 | 10,000,000 |
| Q2 2023 | 1,500,000 | -1,800,000 | 9,500,000 |
| Q3 2023 | 1,700,000 | -1,600,000 | 9,000,000 |
Recent Stock Performance
The stock performance of electroCore, Inc. reflects the market's reception of its recent developments:
| Date | Stock Price (in USD) | Market Capitalization (in USD) | Volume Traded |
|---|---|---|---|
| September 30, 2023 | 2.50 | 40,000,000 | 250,000 |
| October 15, 2023 | 3.00 | 48,000,000 | 300,000 |
electroCore, Inc. (ECOR) Mission Statement
Overview of electroCore, Inc.
electroCore, Inc. is a commercial-stage medical technology company focused on developing and commercializing non-invasive vagus nerve stimulation (nVNS) therapies for the treatment of various neurological and psychiatric disorders. The company utilizes its proprietary nVNS platform to create a new standard of care in patient treatment.
Core Mission Statement
The mission of electroCore, Inc. is to improve the quality of life for patients suffering from chronic debilitating conditions through innovative therapies. The company aims to achieve this by:
- Transforming patient care with non-invasive treatments.
- Delivering groundbreaking solutions to common neurological disorders.
- Fostering a culture of innovation and scientific excellence.
Financial Performance
As of the most recent fiscal year, electroCore reported a total revenue of $8.5 million. The company's financial performance can be summarized through the following key figures:
| Year | Total Revenue ($ million) | Net Income ($ million) | R&D Expenses ($ million) | SG&A Expenses ($ million) |
|---|---|---|---|---|
| 2022 | 8.5 | -12.3 | 5.1 | 10.4 |
| 2021 | 5.2 | -15.0 | 4.2 | 9.8 |
| 2020 | 2.6 | -17.5 | 3.5 | 7.9 |
Market Focus
electroCore has established a robust market presence focusing on a variety of indications, including:
- Cluster Headaches
- Migraines
- Epilepsy
- Depression
Strategic Initiatives
To support its mission, electroCore is committed to:
- Expanding its clinical trials to gather more data on nVNS efficacy.
- Enhancing partnerships with healthcare providers and payers.
- Investing in educational programs for physicians and patients.
Recent Developments
In 2023, electroCore announced the completion of a pivotal clinical trial demonstrating the effectiveness of its nVNS therapy for migraine treatment, with a statistically significant reduction in headache days reported by 60% of participants.
Company Vision
electroCore envisions a future where its therapies are a vital component of standard treatment protocols for neurological and psychiatric disorders, fostering a healthcare environment that prioritizes patient-centered approaches.
How electroCore, Inc. (ECOR) Works
Company Overview
Company Overview
electroCore, Inc. (ECOR) is a commercial-stage medical technology company that develops and delivers non-invasive vagus nerve stimulation (nVNS) therapies. The company's focus is on the treatment of various neurological and psychiatric conditions, including migraine and cluster headaches.
Product Portfolio
electroCore's flagship product is the gammaCore device, designed for the treatment of migraine and cluster headaches. Key features include:
- Device form factor: Handheld portable device
- Delivery method: Non-invasive stimulation of the vagus nerve
- FDA approval: Received in 2017 for migraine treatment
Market Positioning
The company primarily targets the neurology market, which was estimated to be worth approximately $118 billion in 2020, with a projected CAGR of around 4.5% from 2021 to 2028.
Financial Performance
As of the end of Q2 2023, electroCore reported the following financial metrics:
| Metric | Value |
|---|---|
| Revenue (Q2 2023) | $2.6 million |
| Net Loss (Q2 2023) | $(5.9) million |
| Cash and Cash Equivalents (June 30, 2023) | $15.2 million |
| Total Assets (Q2 2023) | $35.7 million |
| Total Liabilities (Q2 2023) | $17.4 million |
Regulatory and Approvals
electroCore has received various regulatory approvals for its products:
- FDA 510(k) clearance for gammaCore in 2017
- CE Mark for gammaCore in the European Union
- In-progress studies for additional indications, including epilepsy and depression
Research and Development
As of 2023, electroCore has invested significantly in R&D, allocating approximately $3 million in 2022 alone to enhance its product offerings and validate new clinical applications.
Distribution and Sales Channels
electroCore employs a multi-faceted distribution strategy that includes:
- Direct sales to healthcare providers
- Partnerships with distributors
- Online sales through its website and telehealth platforms
The company has expanded its sales force to increase market penetration, which is anticipated to boost sales by 20% in 2023 compared to the previous year.
Strategic Partnerships
To facilitate growth, electroCore has engaged in strategic partnerships:
- Collaboration with academic institutions for clinical studies
- Partnership with telehealth providers to broaden patient access
- Alliances with insurance companies for reimbursement support
Competitive Landscape
In the neuromodulation market, electroCore faces competition from several companies:
- Cefaly Technology
- NeuraLace Medical
- Abbott Laboratories
Market share analysis shows that electroCore holds approximately 10% of the migraine treatment device market as of 2023.
Future Outlook
The future growth of electroCore is supported by:
- New product development targeting additional indications
- Intensified marketing efforts in the direct-to-consumer segment
- Expansion into international markets beyond the US and Europe
Projected revenue for fiscal year 2024 is estimated to reach $12 million, assuming successful market penetration and continued adoption of nVNS therapy.
How electroCore, Inc. (ECOR) Makes Money
Revenue Sources
electroCore, Inc. primarily generates revenue through:
- Product Sales: Sales of its non-invasive neuromodulation therapy devices.
- Reimbursement: Securing reimbursements from insurance providers for its therapies.
- Partnerships and Collaborations: Entering strategic partnerships for research and development.
Product Sales
electroCore's primary product, the gammaCore device, is used for the acute treatment of cluster headaches and migraine attacks. As of 2023, the company reported:
| Year | Units Sold | Revenue from Product Sales (in millions) |
|---|---|---|
| 2020 | 10,000 | $5.0 |
| 2021 | 12,500 | $7.5 |
| 2022 | 15,000 | $9.0 |
| 2023 (Projected) | 20,000 | $12.0 |
Reimbursement Strategy
The company has been actively working to secure reimbursement codes for its devices. The results of these efforts as of the end of 2022 are as follows:
| Reimbursement Source | Status | Estimated Coverage Rate |
|---|---|---|
| Medicare | Approved | 70% |
| Medicaid | Pending | 50% |
| Private Insurance | Varies | 60% average |
Partnerships and Collaborations
In 2022, electroCore entered into several strategic collaborations to enhance its research capabilities and market presence:
- Collaboration with Mount Sinai Health System: Aimed at developing new applications for the gammaCore device.
- Partnership with Novartis: Focused on research related to migraine therapeutics.
- Agreement with Medtronic: Exploring integration of gammaCore with Medtronic’s existing therapies.
Financial Performance
As of the end of Q2 2023, electroCore reported the following financial metrics:
| Metric | Amount (in millions) |
|---|---|
| Total Revenue | $15.0 |
| Net Income | -$5.0 |
| Operating Expenses | $10.0 |
| Cash Reserves | $20.0 |
Market Presence
electroCore has expanded its market presence with the following statistics:
| Region | Market Share (%) | Estimated Patients Treated |
|---|---|---|
| United States | 30% | 75,000 |
| Europe | 15% | 25,000 |
| Other (Asia, Canada, etc.) | 5% | 10,000 |
electroCore, Inc. (ECOR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support